David Gervais

816 total citations
42 papers, 585 citations indexed

About

David Gervais is a scholar working on Molecular Biology, Public Health, Environmental and Occupational Health and Literature and Literary Theory. According to data from OpenAlex, David Gervais has authored 42 papers receiving a total of 585 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 10 papers in Public Health, Environmental and Occupational Health and 5 papers in Literature and Literary Theory. Recurrent topics in David Gervais's work include Acute Lymphoblastic Leukemia research (10 papers), Protein purification and stability (9 papers) and Biochemical and Molecular Research (6 papers). David Gervais is often cited by papers focused on Acute Lymphoblastic Leukemia research (10 papers), Protein purification and stability (9 papers) and Biochemical and Molecular Research (6 papers). David Gervais collaborates with scholars based in United Kingdom, United States and Canada. David Gervais's co-authors include Angela H. Beckett, Michael J. McCluskie, James Merson, Ningli Zhang, Heather L. Davis, Michelle Benoit, J Zittoun, Hélène Ogier de Baulny, Charles Pierrot‐Deseilligny and Françis Bolgert and has published in prestigious journals such as PLoS ONE, Analytical Biochemistry and Radiology.

In The Last Decade

David Gervais

31 papers receiving 557 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Gervais United Kingdom 12 336 123 88 81 74 42 585
Susan Pollak United States 14 285 0.8× 137 1.1× 81 0.9× 55 0.7× 18 0.2× 26 553
Guillermo I. Tous United States 11 408 1.2× 12 0.1× 158 1.8× 41 0.5× 23 0.3× 16 605
James J. Greene United States 15 378 1.1× 65 0.5× 25 0.3× 122 1.5× 34 0.5× 32 691
Rohini Deshpande United States 12 404 1.2× 33 0.3× 107 1.2× 169 2.1× 20 0.3× 16 715
Р. С. Есипов Russia 15 537 1.6× 19 0.2× 36 0.4× 20 0.2× 34 0.5× 103 713
Michael Schneider United States 10 413 1.2× 21 0.2× 38 0.4× 150 1.9× 29 0.4× 20 645
Nicholas Buss United States 12 402 1.2× 22 0.2× 219 2.5× 135 1.7× 19 0.3× 22 735
Allyn M. Kaufmann United States 7 310 0.9× 21 0.2× 103 1.2× 57 0.7× 10 0.1× 7 643
T W Sery United States 11 141 0.4× 49 0.4× 68 0.8× 55 0.7× 20 0.3× 20 482
Steven D. Stroop United States 16 626 1.9× 445 3.6× 44 0.5× 54 0.7× 5 0.1× 23 1.2k

Countries citing papers authored by David Gervais

Since Specialization
Citations

This map shows the geographic impact of David Gervais's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Gervais with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Gervais more than expected).

Fields of papers citing papers by David Gervais

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Gervais. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Gervais. The network helps show where David Gervais may publish in the future.

Co-authorship network of co-authors of David Gervais

This figure shows the co-authorship network connecting the top 25 collaborators of David Gervais. A scholar is included among the top collaborators of David Gervais based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Gervais. David Gervais is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gervais, David, et al.. (2021). Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase. Investigational New Drugs. 40(1). 21–29. 7 indexed citations
2.
Roberts, David S., et al.. (2020). Determination of extent of PEGylation using denaturing capillary isoelectric focussing. Analytical Biochemistry. 611. 113953–113953. 4 indexed citations
3.
Gervais, David. (2020). Acidic isoforms of Erwinase form part of the product: Correlation with clinical experience. Biologicals. 64. 28–33. 1 indexed citations
4.
Beckett, Angela H. & David Gervais. (2019). What makes a good new therapeutic l-asparaginase?. World Journal of Microbiology and Biotechnology. 35(10). 152–152. 90 indexed citations
5.
Gervais, David, et al.. (2017). Robust quantitation of basic-protein higher-order aggregates using size-exclusion chromatography. Journal of Pharmaceutical and Biomedical Analysis. 139. 215–220. 8 indexed citations
6.
Gervais, David, et al.. (2016). Understanding the process-induced formation of minor conformational variants of Erwinia chrysanthemi l-asparaginase. Enzyme and Microbial Technology. 98. 26–33. 3 indexed citations
7.
McCluskie, Michael J., Jennifer M. Thorn, David Gervais, et al.. (2015). Anti-nicotine vaccines: Comparison of adjuvanted CRM 197 and Qb-VLP conjugate formulations for immunogenicity and function in non-human primates. International Immunopharmacology. 29(2). 663–671. 37 indexed citations
8.
Gervais, David, Patrick Kanda, Lucy H. Elliott, et al.. (2015). Structural Characterisation of Non-Deamidated Acidic Variants of Erwinia chrysanthemi L-asparaginase Using Small-Angle X-ray Scattering and Ion-Mobility Mass Spectrometry. Pharmaceutical Research. 32(11). 3636–3648. 12 indexed citations
9.
Gervais, David, et al.. (2014). Recombinant Deamidated Mutants of Erwinia chrysanthemi l-Asparaginase Have Similar or Increased Activity Compared to Wild-Type Enzyme. Molecular Biotechnology. 56(10). 865–877. 25 indexed citations
10.
Gervais, David, et al.. (2014). Measurement of Subvisible Particulates in Lyophilised Erwinia chrysanthemi l-asparaginase and Relationship with Clinical Experience. The AAPS Journal. 16(4). 784–790. 4 indexed citations
11.
McCluskie, Michael J., David C. Pryde, David Gervais, et al.. (2013). Enhancing immunogenicity of a 3′aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates. International Immunopharmacology. 16(1). 50–56. 42 indexed citations
12.
Pryde, David C., Lyn H. Jones, David Gervais, et al.. (2013). Selection of a Novel Anti-Nicotine Vaccine: Influence of Antigen Design on Antibody Function in Mice. PLoS ONE. 8(10). e76557–e76557. 66 indexed citations
13.
Gervais, David, et al.. (2013). Control of process-induced asparaginyl deamidation during manufacture of Erwinia chrysanthemi l-asparaginase. Process Biochemistry. 48(9). 1311–1316. 14 indexed citations
14.
Gervais, David, et al.. (2012). Validation of a 30-year-old process for the manufacture of l-asparaginase from Erwinia chrysanthemi. Bioprocess and Biosystems Engineering. 36(4). 453–460. 29 indexed citations
15.
Roze, Emmanuel, David Gervais, Sophie Demeret, et al.. (2003). Neuropsychiatric Disturbances in Presumed Late-Onset Cobalamin C Disease. Archives of Neurology. 60(10). 1457–1457. 79 indexed citations
16.
Dionnet, Frédéric, et al.. (2000). Experimental Investigation of an Optical Direct Injection S.I. Engine Using Fuel-Air Ratio Laser Induced Fluorescence. SAE technical papers on CD-ROM/SAE technical paper series. 1. 10 indexed citations
17.
Gervais, David. (1996). T. F. Powys: Invention and Myth. English Journal of the English Association. 45(181). 62–78. 1 indexed citations
18.
Gervais, David, et al.. (1995). Walter B. Cannon, MD.. Radiology. 194(1). 31–32. 2 indexed citations
19.
Gervais, David. (1989). Deciphering America: The American Scene. The Cambridge Quarterly. XVIII(4). 349–362. 1 indexed citations
20.
Gervais, David. (1978). Flaubert and Henry James. Palgrave Macmillan UK eBooks. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Susan Pollak Breakdown of academic impact, for papers by Guillermo I. Tous Breakdown of academic impact, for papers by James J. Greene Breakdown of academic impact, for papers by Rohini Deshpande Breakdown of academic impact, for papers by Р. С. Есипов Breakdown of academic impact, for papers by Michael Schneider Breakdown of academic impact, for papers by Nicholas Buss Breakdown of academic impact, for papers by Allyn M. Kaufmann Breakdown of academic impact, for papers by T W Sery Breakdown of academic impact, for papers by Steven D. Stroop
Rankless by CCL
2026